Allopole-A
Allopole-A is a Plk1 inhibitor with an IC50 of 1.4-2.5 μM against human Plk1 PBD1. Allopole-A binds to the allosteric W-F pocket in Plk1 PBD1, displacing the L2 loop, thereby disrupting water-mediated phospho-ligand binding interactions and promoting inhibitory interactions between the kinase domain and PBD to suppress Plk1 kinase activity. Allopole-A can be used in studies of human cancers with plk1 overexpression.
For research use only. We do not sell to patients.
- CAS No.: 3057557-03-3
- Formula: C11H9ClN4OS2
- Molecular Weight:312.80
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PLK1 PBD 1.4-2.5 μM (IC50) |
In Vitro
Allopole-A inhibits PBD1-dependent phosphopeptide binding to full-length Plk1 with an IC50 of 1.4 μM in the ELISA-based assay[1].
Allopole-A (2.5 μM; 30 min) displays strong specificity for inhibiting phosphopeptide binding to Plk1 PBD (PBD1) over PBD2 and PBD3, with an IC50 of 2.5 μM in the fluorescence polarization assay[1].
Allopole-A (20 min pre-incubation at 25 °C, followed by 30 min kinase reaction at 30 °C) directly inhibits the intrinsic catalytic activity of purified recombinant human Plk1 in an in vitro kinase assay[1].
Mutation of the Plk1 PBD1 residue F559 to charged residues completely abolishes Allopole-A's capacity to inhibit phosphopeptide binding to PBD1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3057557-03-3
-
Molecular Weight 312.80
-
Formula C11H9ClN4OS2
-
SMILES
S=C1NN=C(N1C2=C3SC(Cl)=C2)N(C3=O)CC4CC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)